Free Delivery Over $100
|
|
|||
|
||||
OverviewFull Product DetailsAuthor: Katherine Fierlbeck , Janice Graham , Matthew HerderPublisher: University of Toronto Press Imprint: University of Toronto Press Dimensions: Width: 15.00cm , Height: 2.50cm , Length: 22.90cm Weight: 0.540kg ISBN: 9781487529031ISBN 10: 1487529031 Pages: 304 Publication Date: 22 June 2021 Audience: College/higher education , Professional and scholarly , Tertiary & Higher Education , Professional & Vocational Format: Hardback Publisher's Status: Active Availability: Manufactured on demand  We will order this item for you from a manufactured on demand supplier. Table of Contents1. Introduction Katherine Fierlbeck, Janice Graham, and Matthew Herder 2. Transparency, Pharmaceuticals, and the Problem of Policy Change Katherine Fierlbeck 3. Data Transparency and Pharmaceutical Regulation in Europe: Road to Damascus, or Room without a View? Courtney Davis, Shai Mulinari, and Tom Jefferson 4. FDA and Health Canada: Similar Origins, yet Divergent Paths and Approaches to Transparency Margaret McCarthy and Joe Ross 5. Clinical Trial Data Transparency in Canada: Mapping the Progress from Laggard to Leader Marc-André Gagnon, Matthew Herder, Janice Graham, Katherine Fierlbeck, and Anna Danyliuk 6. How Clinical Study Information Transparency Can Fail to Serve Its Purpose, and How the Essential Medicines Concept Can Help Nav Persaud 7. Speak No Secrets: (Non)transparency in Health Canada’s Communications about Pharmaceutical Regulation Joel Lexchin 8. Economic Ghost-Management in the Pharmaceutical Sector Marc-Andre Gagnon 9. Balancing the Privacy Rights of Research Participants with the Public Interest in Clinical Drug Trials Data in the Context of Rare Diseases Kanksha Mahadevia Ghimire and Trudo Lemmens 10. The European Registration of the Pandemic Influenza Vaccine Pandemrix: A Case Study of the Consequences of Poor Clinical Data Transparency Tom Jefferson 11. Sharing Data and Ideas for Good Health: How Researchers Can Sustain an Ethical and Transparent Health System Rita Banzi 12. Conclusion Katherine Fierlbeck, Janice Graham, and Matthew HerderReviews"""A superb evaluation of accountability in the pharmaceutical sector. Fierlbeck, Graham, Herder, and the contributors offer an authoritative and insightful assessment of the limited transparency that prevents us from seeing what is really happening as new drugs are assessed and approved. The authors compare international approaches that offer perspectives on how we can keep our trust in the safety of medicines and the stakeholders involved in regulatory processes.""--Mary E. Wiktorowicz, Professor of Global Health Governance and Policy and Associate Director of the Dahdaleh Institute for Global Health Research, York University ""Transparency, Power, and Influence in the Pharmaceutical Industry is thoroughly researched, extremely well documented, and well written. The contributors are superbly acquainted with the literature on the subjects they write about, and I know many of them encounter their world as both public-interest academics and advocates, people who pursue studies in the public interest and carry out their academic work in the spirit of making the world a more just place.""--Alan Cassels, Drug Policy Researcher, University of Victoria" Transparency, Power, and Influence in the Pharmaceutical Industry is thoroughly researched, extremely well documented, and well written. The contributors are superbly acquainted with the literature on the subjects they write about, and I know many of them encounter their world as both public-interest academics and advocates, people who pursue studies in the public interest and carry out their academic work in the spirit of making the world a more just place. - Alan Cassels, Drug Policy Researcher, University of Victoria A superb evaluation of accountability in the pharmaceutical sector. Fierlbeck, Graham, Herder, and the contributors offer an authoritative and insightful assessment of the limited transparency that prevents us from seeing what is really happening as new drugs are assessed and approved. The authors compare international approaches that offer perspectives on how we can keep our trust in the safety of medicines and the stakeholders involved in regulatory processes. - Mary E. Wiktorowicz, Professor of Global Health Governance and Policy and Associate Director of the Dahdaleh Institute for Global Health Research, York University Author InformationKatherine Fierlbeck is the McCulloch Professor of Political Science at Dalhousie University, with a cross-appointment as professor of Community Health and Epidemiology. Janice Graham is a professor of Paediatrics (infectious diseases) and Medical Anthropology, and the University Research Professor at Dalhousie University. Matthew Herder is the director of the Health Law Institute and an associate professor of Medicine and Law at Dalhousie University. Tab Content 6Author Website:Countries AvailableAll regions |
||||
